Regencell Bioscience Securities Class Action
Analysis based on 6 articles · First reported May 19, 2026 · Last updated Jun 01, 2026
The class action lawsuit and DOJ investigation into Regencell Bioscience Holdings' alleged market manipulation and misleading statements have caused a significant drop in the company's share price. This event highlights the risks associated with market volatility and regulatory scrutiny, potentially impacting investor confidence in similar biotechnology firms.
Faruqi & Faruqi is investigating and has filed a federal securities class action lawsuit against Regencell Bioscience Holdings Limited. The lawsuit alleges that Regencell Bioscience Holdings and its executives made false and misleading statements, failing to disclose that the company was vulnerable to market manipulation, which exposed investors to significant financial risk. This vulnerability led to a U.S. Department of Justice investigation into the trading of Regencell Bioscience Holdings' ordinary shares. Following the disclosure of the DOJ investigation on October 31, 2025, Regencell Bioscience Holdings' share price fell by 18.56%. Investors who suffered losses between October 28, 2024, and October 31, 2025, are encouraged to seek the role of lead plaintiff in the class action by the June 23, 2026 deadline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard